Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 7/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9038677 | 0.85 | CYP1A2 (0.57) | CYP1A2CYP2A6TDP1ALDH1A1LMNA | |
| SCHEMBL30661085 | 0.84 | CYP2A6 (0.52) | CYP1A2CYP2A6TDP1ALDH1A1LMNA | |
| SCHEMBL599403 | 0.84 | CYP2A6 (0.52) | CYP1A2CYP2A6TDP1ALDH1A1LMNA | |
| SCHEMBL7089537 | 0.83 | CYP1A2 (0.46) | CYP1A2CYP2A6TDP1ALDH1A1LMNA | |
| SCHEMBL8562301 | 0.83 | CYP1A2 (0.54) | CYP1A2CYP2A6TDP1ALDH1A1LMNA | |
| SCHEMBL599191 | 0.81 | CYP1A2 (0.62) | CYP1A2CYP2A6TDP1ALDH1A1HPGD | |
| SCHEMBL597878 | 0.81 | CYP1A2 (0.73) | CYP1A2CYP2A6TDP1ALDH1A1LMNA | |
| SCHEMBL598782 | 0.80 | HPRT1 (0.64) | CYP1A2CYP2A6TDP1ALDH1A1LMNA | |
| SCHEMBL28996719 | 0.80 | HPRT1 (0.64) | CYP1A2CYP2A6TDP1ALDH1A1LMNA | |
| SCHEMBL19154163 | 0.79 | CYP1A2 (0.45) | CYP1A2CYP2A6TDP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108254341-A | Double quantum dot fluorescent two-dimensional probe malathion and ethion identification quantitative detection method and device | 安徽大学 | 2018-07-06 | — | — | CN | claimed |
| CN-104651814-A | Chemical copper plating solution and chemical copper plating method | SUR PREC METAL TECHNOLOGY CO LTD | 2015-05-27 | — | — | CN | claimed |
| CN-110143910-B | Preparation method of polysubstituted pyrrolidone derivative | 华侨大学 | 2022-04-05 | — | — | CN | disclosed |
| CN-110272357-A | A kind of preparation method of alkenyl cyanides | 中国科学院上海有机化学研究所 | 2019-09-24 | — | — | CN | disclosed |
| CN-109651202-A | Utilize the method for dimethyl sulfoxide ylide, amine and carbon dioxide synthesis of carbamates | 华南理工大学 | 2019-04-19 | — | — | CN | disclosed |
| CN-109400464-A | The preparation method of 5- acetyl bromide propionic acid | 湖北大学 | 2019-03-01 | — | — | CN | disclosed |
| CN-104651814-A | Chemical copper plating solution and chemical copper plating method | SUR PREC METAL TECHNOLOGY CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8957223-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130184328-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | disclosed |
| EP-1569652-A2 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | Pharmasset Ltd. (BB) | 2005-09-07 | — | — | EP | disclosed |
| US-6908924-B2 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | PHARMASSET, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184328-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | CYP1A2 3615/4885CYP2A6 3078/4885TDP1 3627/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | CYP1A2 810/4885CYP2A6 1101/4885TDP1 1215/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | CYP1A2 1161/4885CYP2A6 1193/4885TDP1 2045/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | CYP1A2 1174/4885CYP2A6 1296/4885TDP1 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.